Evidence map›Paper›PMID 42018002›Full record

ArticleCancer immunology, immunotherapy : CII2026

CD39/CD73-mediated immunosuppression and tumor aggressiveness in bladder cancer.

Frederico Furriel, Paula Laranjeira, Margarida Pereira, Sandra Silva, Isabel Silva, Guilherme Fontinha, Vítor Sousa, Célia Gomes, Belmiro Parada, Artur Paiva

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Frederico FurrielFaculty of Medicine, University of Coimbra (FMUC), Coimbra, Portugal.
Paula LaranjeiraFlow Cytometry Unit, Clinical Pathology Department, Hospitais da Universidade de Coimbra, Unidade Local de Saúde de Coimbra, Coimbra, Portugal.
Margarida PereiraFlow Cytometry Unit, Clinical Pathology Department, Hospitais da Universidade de Coimbra, Unidade Local de Saúde de Coimbra, Coimbra, Portugal.
Sandra SilvaFlow Cytometry Unit, Clinical Pathology Department, Hospitais da Universidade de Coimbra, Unidade Local de Saúde de Coimbra, Coimbra, Portugal.
Isabel SilvaFlow Cytometry Unit, Clinical Pathology Department, Hospitais da Universidade de Coimbra, Unidade Local de Saúde de Coimbra, Coimbra, Portugal.
Guilherme FontinhaUnidade Local de Saúde de Coimbra, Department of Pathology, Hospitais da Universidade de Coimbra, Coimbra, Portugal.
Vítor SousaFaculty of Medicine, University of Coimbra (FMUC), Coimbra, Portugal.
Célia GomesCIBB-Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal.
Belmiro Parada *CIBB-Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal. parada.belmiro@gmail.com.ORCID http://orcid.org/0000-0002-9911-4926
Artur Paiva *Flow Cytometry Unit, Clinical Pathology Department, Hospitais da Universidade de Coimbra, Unidade Local de Saúde de Coimbra, Coimbra, Portugal.

Funding

CUF BDM/2021Liga Portuguesa Contra o Cancro 03/22Portuguese Association of Urology BI-APU 2019
6 · The paper itself

Abstract

Urothelial bladder cancer (BCa) is marked by high recurrence and mortality, and the efficacy of PD-1/PD-L1 immunotherapy remains limited because of immune evasion. The adenosinergic pathway (AP), mediated by ectonucleotidases CD39 and CD73, is a key immunosuppressive mechanism, but its role in BCa remains unclear. We conducted an integrated immunophenotypic analysis of peripheral blood (PB) and the tumor microenvironment (TME) from 39 patients with BCa and 14 healthy controls using multicolor flow cytometry and immunohistochemistry. High-risk (HR) patients exhibited systemic immunosuppression, characterized by an elevated neutrophil-to-lymphocyte ratio and increased circulating regulatory T cells (Tregs), along with reduced cytotoxic γδ T cells and diminished Th1/Tc1 functional subtypes. In the TME, we observed reduced CD8

Indexed as

5'-NucleotidaseAntigens, CDApyraseImmune ToleranceUrinary Bladder NeoplasmsAgedBiomarkers, TumorFemaleGPI-Linked ProteinsHumansLymphocytes, Tumor-InfiltratingMaleMiddle AgedT-Lymphocytes, RegulatoryTumor Microenvironment5'-NucleotidaseAntigens, CDApyraseBiomarkers, TumorCD39 antigenENTPD1 protein, humanGPI-Linked ProteinsNT5E protein, humanAdenosinergic pathwayCD39CD73Immune profilingTumor immune evasionUrinary bladder neoplasms

Identifiers

PMID42018002
PMCPMC13103164

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.